Company Filing History:
Years Active: 2021-2024
Title: Innovations and Contributions of Inventor Nan Li
Introduction
Nan Li is a prominent inventor based in Laurel, MD (US), known for his significant contributions to the field of biomedical research. He holds a total of five patents, showcasing his innovative approach to developing therapies for cancer treatment. His work primarily focuses on the creation of monoclonal antibodies and chimeric antigen receptor (CAR) T cells, which have the potential to revolutionize cancer diagnostics and therapies.
Latest Patents
Among his latest patents, one notable invention is the development of cross-species single domain antibodies targeting mesothelin for treating solid tumors. This patent describes camel single-domain monoclonal antibodies that specifically bind to human and mouse mesothelin. The disclosed CAR T cells and antibody conjugates based on these mesothelin-specific antibodies can be utilized in the diagnosis or treatment of mesothelin-positive cancers. Another significant patent involves high affinity monoclonal antibodies targeting glypican-1 (GPC1). This invention details monoclonal antibodies that specifically bind to GPC1, along with CAR T cells, immunotoxins, and other antibody conjugates. These innovations can be applied in the diagnosis or treatment of GPC1-positive pancreatic cancer and other related cancers.
Career Highlights
Nan Li is currently affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His work at this esteemed institution allows him to collaborate with leading experts in the field and contribute to groundbreaking research that addresses critical health challenges.
Collaborations
Some of his notable coworkers include Mitchell Ho and Dimiter Stanchev Dimitrov. Their collaborative efforts enhance the research environment and foster innovation in cancer treatment methodologies.
Conclusion
Nan Li's contributions to the field of biomedical research through his patents and collaborations highlight his commitment to advancing cancer therapies. His innovative work continues to pave the way for new diagnostic and treatment options for patients worldwide.